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Abstract 
Extracellular vesicles (EVs) are naturally occurring cargo delivery vesicles that have recently received 
considerable attention for their roles in intercellular communication in many physiological and 
pathological processes, including tumourigenesis. EVs generated by different tissues demonstrated 
specific homing: in particular, cancer-derived EVs showed a selective tropism for the tumor tissue from 
which the vesicles originated. For this property, EVs have been proposed as drug delivery tools for 
anti-cancer therapies, although the limited knowledge about their in vivo tropism hinders their therapeutic 
applications. The current study aimed to characterize the targeting properties of cancer-derived EVs in 
vitro and their biodistribution in vivo, by using an imaging approach. 
Methods: EVs were generated from: i) murine lung (LL/2) and colon (MC-38) cancer lines, ii) human lung 
cancer cell line (A549) and iii) human liver biopsy samples from healthy individuals. EVs were loaded with 
fluorescent dyes alone or in combination with a biopharmaceutical agent, the oncolytic adenovirus (OV), 
characterized for charge and size and tested for their activity in cancer cell lines. Finally, optical imaging 
was extensively applied to study in vivo and ex vivo the biodistribution of EVs originated from different 
sources in different mouse models of cancer, including xenograft, syngeneic graft and the MMTV-NeuT 
genetically modified animal. 
Results: We initially demonstrated that even loading EVs even with a large biopharmaceutical oncolytic 
viruses (OVs) did not significantly change their charge and dimension properties, while increasing their 
anti-neoplastic activity compared to the virus or EVs alone. Interestingly, this activity was observed even 
if the EVs derived from lung cancer were applied to colon carcinoma cell lines and vice versa, suggesting 
that the EV uptake occurred in vitro without any specificity for the cancer cells from which the vesicles 
originated. When administered i.v (intravenously) to the mouse models of cancer, the tumour-derived 
EVs, but not the EVs derived from a healthy tissue, demonstrated a selective accumulation of the 
fluorescence at the tumour site 24 h after injection; adding OVs to the formulation did not change the 
tumour-specific tropism of the EVs also in vivo. Most interestingly, the in vivo experiments confirmed the 
in vitro observation of the generalized tropism of tumour-derived EVs for any neoplastic tissue, 
independent of the tumour type or even the species originating the vesicles.  
Conclusions: Taken together, our in vitro and in vivo data demonstrate for the first time a heterologous, 
cross-species tumour-tropism for cancer-derived EVs. This finding challenges our current view on the 
homing properties of EVs and opens new avenues for the selective delivery of diagnostic/therapeutic 
agents to solid tumours. 
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Intercellular communication regulates both 
biological and pathological processes [1]. 
Cells continuously cross-talk by using different 
networks such as paracrine signalling, transport 
through gap junctions and extracellular vesicles (EVs) 
[1]. EVs are a heterogeneous group of cells-derived 
membrane vesicles that are present in body fluids and 
are able to carry proteins, lipids and coding or 
noncoding RNA molecules [2]. These vesicles 
participate in the intercellular communication under 
both physiological and pathological conditions; in 
healthy individuals they are involved in the 
regulation and maintenance of reproduction, cell 
death, tissue repair and inflammation [3], while in 
tumourigenesis, EVs contribute to the acquisition of 
different hallmarks of cancer including inhibition of 
cell death, invasion, metastasis and 
immunosuppression [4,5]. In this scenario EVs are 
emerging as key mediators in pathological processes 
and can act at local or systemic levels [6]. The 
mechanism by which the vesicles actively participate 
in the neoplastic transformation may involve the 
transfer of proteins, lipids and nucleic acids after a 
physical interaction with target cells [7,8]. 
Several mechanisms have been proposed for EV 
uptake [9]: EVs can either fuse with the cellular 
plasma membrane to deliver their cargo [10], or be 
internalized by cells. It has also been suggested that 
EVs could use the energy-dependent 
receptor-mediated endocytosis, including 
clathrin-mediated endocytosis, caveolin-mediated 
endocytosis [11,12], micropinocytosis [13] and 
phagocytosis [14]. Since the EV internalization process 
could occur through multiple pathways, the exact 
mechanisms driving the EVs’ delivery to a specific 
target cell remain elusive, although selected 
protein-protein interactions have been proposed for 
some tissue-specific uptake [12,15] as in the case of 
tumour derived EVs that preferentially home to the 
cancer tissue originating the vesicles compared to the 
healthy tissues [15]. This tumor tropism may be the 
consequence of functional properties specifically 
acquired by the cancer-derived EVs, which have 
different biogenesis mechanisms [16,17], cargo uptake 
[18,19] and expression of specific membrane proteins 
and antigens [20,21], compared with vesicles 
originating from non-malignant cells.  
EVs’tumor-specific tropism, absence of 
immunogenicity, natural composition, and ability to 
be loaded with small molecules and biologics are 
highly attractive features that raise the possibility of 
using EVs as carriers for theranostics [22–24]. Indeed, 
EVs were recently used for the delivery of OVs [25–27] 
and chemotherapeutic drugs [28], providing evidence 
of a tumour-targeted delivery and increased efficacy 
of the treatments in preclinical models [24]. Although 
highly attractive, the use of EVs in clinical 
applications remains limited because the molecular 
basis of their tropism and targeted delivery to cancer 
cells has not been thoroughly elucidated to date, 
which is the basis for developing an effective 
EV-driven anti-neoplastic therapy [29]. Indeed, it is 
still not clear whether the tumour tissue from which 
the EVs originate dictates their strict tissue tropism 
[15,30,31], since there are controversial reports 
indicating that this tumour specificity may be lacking 
[9]. Thus, despite the intense research in the field, little 
is known about the EVs’ biodistribution and their in 
vivo trafficking [32–34]. 
In this study, we investigated the tropism of 
murine lung and colon cancer-derived EVs labelled 
with fluorescent dyes [24,35] in vitro and in vivo, by 
using imaging technology. We demonstrated the 
existence of a heterologous, cross-species cancer- 
specific homing of the vesicles. This homing 
capability is not modified by loading the vesicles with 
a large therapeutic agent such as an OV [36–40], 
suggesting the possibility of generating EVs from cell 
lines even from different species which can be used to 
deliver theranostics to different tumour types.  
Materials and Methods 
Cell culture 
LL/2 mouse lung cancer cell line, MC-38 mouse 
colon cancer cell line, C2C12 mouse myoblast cell line 
and A549 human lung cancer cell line were purchased 
from the American Type Culture Collection (ATCC, 
USA). The cells were cultured at 37 °C and 5 % CO2 in 
Dulbecco’s modified eagle medium (DMEM, Lonza, 
Switzerland) supplemented with 10 % fetal bovine 
serum (FBS, Gibco Laboratories, USA), 1 % of 100 
u/mL penicillin/streptomycin (Gibco Laboratories) 
and 1% L-glutamine (Gibco Laboratories).  
Oncolytic virus  
Oncolytic adenovirus Ad5/3-CD40L has been 
characterized by molecular analyses (PCR, 
sequencing) and functionality assay (CD40 ligand), 
[41] to check virus genome stability, integrity and 
oncolytic properties. Viral stocks were expanded in 
human lung cancer cell line A549 and purified on 
cesium chloride gradients. The viral particle 
concentration was determined by OD260-reading 
(VP/mL) and standard TCID50 (tissue culture 
infectious dose 50) assay was performed to determine 
infectious particle titer.  





Production of EVs, Lipophilic Dye loaded EVs 
and Indocyanine green loaded EVs 
In order to produce EVs 2.6 ×106 LL/2, 5 ×106 
MC-38 and 2.6 x 106 A549 cells were plated into T-175 
flask in medium supplemented with 5 % FBS. The FBS 
growth media was ultra-centrifuged overnight 
(110 000 x g at 4°C for 18 h, Optima LE-80K 
ultracentrifuge, rotor type 50.2, Beckman Coulter) to 
remove EVs present in the serum.  
EVs were isolated from the conditioned medium 
using differential centrifugation steps. First the 
conditioned medium was centrifuged at 500 x g in 4°C 
for 10 min to pellet cells (Allegra X-15R Centrifuge, 
Beckman Coulter). Then, the supernatant was 
collected and ultra-centrifuged for 2 h at 100 000 x g in 
4°C, using Optima L-80 XP ultra-centrifuge (Beckman 
Coulter) with rotor SW32Ti (Beckman Coulter). The 
supernatant was aspirated and EV- containing pellets 
re-suspended in PBS (Lonza) 100 μL and stored for 
few days at - 80 °C.  
EVs from patient-derived liver tissue were 
isolated using different ultracentrifugation steps. 
Firstly, liver tissue was minced and passed through a 
0.2 micron filter for subsequent ultra-centrifugation. 
Then, samples were ultra-centrifuged for 2 h at 100 
000 x g and 4°C, using Optima L-80 XP 
ultra-centrifuge (Beckman Coulter) with rotor SW32Ti 
(Beckman Coulter). The supernatant was aspirated 
and pellets containing EV-Virus re-suspended in PBS 
100μL and stored for few days at - 80 °C. 
EVs from LL/2 and MC-38 cells were loaded 
with DiD lipophilic dye (EV-DiD) as previously 
described [24,42] and prepared by incubating 1 × 108- 
5 ×109 EVs for 1 hour at RT with 5 μL of DiD (Biotium) 
per mL of EV suspension in PBS. Next, the samples 
were centrifuged at 150 000 x g for 3 h to pellet the 
EVs. The supernatant containing unbound DiD was 
removed, and the EV-pellet was washed by 
suspending it in PBS and pelleting it again at 150 000 x 
g. 
EVs from LL/2 and MC-38 cells were loaded 
with Indocyanine green (EV-ICG) and prepared by 
incubating 1× 108-5×109 EVs in PBS for 12 h at 4°C 
with 10ug/mL ICG (Sigma). Next, the samples were 
centrifuged at 150 000 x g for 3 h to pellet the EVs. The 
supernatant containing unbound ICG was removed, 
and the EV-pellet was washed by suspending it in 
PBS and pelleting it again at 150 000 x g. 
Production of EV-Virus formulations 
EV-encapsulated virus (EV-Virus) were 
produced as previously described [23,24,42], 2.6 x 106 
of LL/2 cells and 5×106 of MC-38 were infected with 
10 viral particles/cell of Ad5D24 and were cultured at 
37 °C and 5 % CO2. 48 h later when most of the cells 
were detached from the culture flask, the culture 
media were collected for EV-Virus isolation using 
differential centrifugation. First the conditioned 
medium was centrifuged at 500 x g and 4°C for 10 
min, to separate the cells (Allegra X-15R Centrifuge, 
Beckman Coulter). Then, the supernatant containing 
EV-Virus was collected and ultra-centrifuged for 2 h 
at 100 000 x g and 4°C, using Optima L-80 XP 
ultra-centrifuge (Beckman Coulter) with rotor SW32Ti 
(Beckman Coulter). The supernatant was aspirated 
and pellets containing EV-Virus re-suspended in PBS 
100μL and stored at - 80 °C. EV-Virus samples were 
incubated in 100 mM NaOH at room temperature for 
20 min in order to inactivate any free not EV 
encapsulated virus present. Free virus used as 
controls was always inactivated for each experiment 
performed as previously reported [23,43]. Samples 
were subsequently neutralized by the addition of HCl 
0.1 M.  
To generate EV-DiD-Virus, the EV-Virus 
formulation was incubated for 1 h at RT in 5 μL of DiD 
per mL of EV suspension in DPBS. Samples were then 
centrifuged at 150 000 x g for 3 h at RT, in order to 
pellet EV-DiD-Virus. The washing procedure was 
repeated using PBS as diluent. The final 
EV-DiD-Virus pellet was re-suspended in 100 μL of 
PBS and stored for few days at -80 °C until use. 
Size distribution analysis by nanoparticle 
tracking analysis (NTA)  
Size distribution and concentration of EV-LL/2, 
EV-MC-38, Virus, EV-Virus-LL/2 and 
EV-Virus-MC-38 formulations were analyzed by NTA 
using Nanosight model LM14 (Nanosight) equipped 
with blue (404 nm, 70 mV) laser and sCMOS camera. 
The samples containing virus were incubated at +95 
°C for 10 min in order to inactivate the viruses. NTA 
was performed for each sample by recording three 90 
s videos, subsequently analyzed using NTA software 
3.0 (Nanosight). The detection threshold was set to 
level 5 and camera level to 15. 
Zeta potential analysis by electrophoretic light 
scattering  
The zeta potential was measured using ZetaSizer 
Nano (Malvern, UK). All the samples were diluted in 
a volume of 800 μL of MilliQ H2O and injected with a 
1 mL syringe in the capillary flow (DTS1070 folded 
capillary cell) for the measurement. An equilibration 
time of 120 s was set on the software to allow the 
samples to stabilize at 25°C inside the measurement 
chamber. Three parallel measurements were 
performed on each sample. 
 






Cryo-EM images were acquired with a FEI Talos 
Arctica 200 kV FEG electron microscope equipped 
with a FEI Falcon 3EC direct electron detector and 
Volta Phase-plate. Prior to Cryo-EV imaging, samples 
were vitrified on a FEI Vitrobot IV apparatus, and 
processed as previously reported. 
Western blot analysis 
Extracellular vesicles preparation (equivalent to 
60 𝜇𝜇g of protein lysates) were boiled at 95oC for 5 min, 
separated on 4-10% SDS-PAGE using 
beta-mercaptoethanol as reducing agent and 
transferred into nitrocellulose membranes 
(Amersham). Membranes were then blocked in 5% 
non-fat dry milk in TBS-T (0.2% Tween-20) at RT and 
incubated overnight with the primary antibodies 
against the exosomal marker CD63 (SAB4301607 
Sigma, 1:1000), TSG101 (4A10 Abcam, 1:500) and CD9 
(C9993 Sigma, 1:500). Immuno-reactive bands were 
visualized with chemiluminescence by using ECLTM 
Western Blotting Analysis System according to the 
manufacturer’s instructions (Amersham). 
MTS cell viability assay  
LL/2 and MC-38 cells were seeded at a density 
of 1×104 cells/well in 96-well plates and maintained 
under standard growth condition. On the following 
day LL/2 cells were treated in triplicates with EVs 
isolated from LL/2 cells (EV-LL/2) (10 particles/cell), 
EVs isolated from MC-38 cells (EV-MC-38) (10 
particles/cell), Virus (10vp/cell), EV-Virus from LL/2 
cells (EV-Virus-LL/2) (10 particles/cell), EV-Virus 
from MC-38 cells (EV-Virus-MC-38) (10 
particles/cell). MC-38 cells were treated in triplicates 
with EVs isolated from MC-38 cells (EV-MC-38) (10 
particles/cell), EVs isolated from LL/2 cells 
(EV-LL/2) (10 particles/cell), Virus (10vp/cell), 
EV-Virus from MC-38 cells (EV-Virus-MC-38) (10 
particles/cell), EV-Virus from LL/2 cells 
(EV-Virus-LL/2) (10 particles/cell). Cell viability was 
determined by MTS assay according to the 
manufacturer's protocol (Cell Titer 96 AQueous One 
Solution Cell Proliferation Assay; Promega, Nacka, 
Sweden). The absorbance was measured with a 
96-wells plate spectrophotometer Varioskan Flash 
Multimode Reader (Thermo Scientific) at 490 nm. The 
experiments were independently performed three 
times with triplicates of each condition in each 
experiment. 
Immunogenicity of tumor cell death in vitro 
Calreticulin (CRT) exposure. LL/2 and MC-38 
cells were seeded in duplicate onto 6 well plates at 
5×105 cells/well. LL/2 cells were treated in triplicates 
with EV-LL/2 (10 particles/cell), EV-MC-38 (10 
particles/cell), Virus (10vp/cell), EV-Virus-LL/2 (10 
particles/cell), EV-Virus-MC-38 (10 particles/cell). 
MC-38 cells were treated in triplicates with EV-MC-38 
(10 particles/cell), EV-LL/2 (10 particles/cell), Virus 
(10vp/cell), EV-Virus-MC-38 (10 particles/cell), 
EV-Virus-LL/2 (10 particles/cell). After 24 h cells 
were harvested and stained with 1:1000 diluted rabbit 
polyclonal anti-Calreticulin antibody (Abcam, 
Cambridge, UK) for 40 min at 4°C subsequently with 
1:100 diluted Alexa-Fluor 488 secondary antibody 
(Invitrogen, Carlsbad, CA) and analyzed by flow 
cytometry (LSR II, BD, Franklin Lakes, NJ). 
ATP release. LL/2 and MC-38 cell lines were 
seeded in triplicates onto 96 well plates at 1×104 
cells/well and treated as mentioned above. 
Supernatants were collected after 48 h and analyzed 
with ATP Determination Kit according to 
manufacturer’s protocol (Promega, Madison, WI) for 
luminometric analysis (Varioscan Flash, 
ThermoFisher Scientific, Waltham, MA). 
In vivo biodistribution study 
All the animal experiments were performed and 
approved by the Italian Ministry of Research and 
University (permission numbers: 12-12-30012012, 
547/2015) and controlled by a Departmental panel of 
experts. C57BL/6 and MMTV-NeuT mice were used 
for the experiments. The acclimatization period was 
14 days prior to LL/2 and MC-38 cancer cell 
injections. Health status of the mice was monitored 
daily and as soon as signs of pain or distress were 
evident they were euthanized. Administration of any 
EV formulation did not produce sign of pain or 
changes in the behavior in the treated animals. 
Murine xenografts were established by injecting 2×106 
LL/2 and 1×106 MC-38 cells s.c. into the neck of 
12-week old male mice. The aim of the fluorescence 
study was to have a direct evidence of the specific 
tropism of different cancer derived EVs encapsulated 
with oncolytic viruses to the tumor, thus the 
fluorescent emission of a lipophilic dye (DiD) and 
Indocyanine green (ICG) was related to the particle 
biodistribution. Therefore, we performed the 
following treatments: DiD (5 μL per mL of EV 
suspension in DPBS), EV-DiD-LL/2 (n=5) (1×108 
particles/tumor), EV-DiD-MC-38 (n=5) (1×108 
particles/tumor), EV-DiD-Virus-LL/2 (n=5) (1×108 
particles/tumor + 1×108 vp/tumor), EV-DiD-Virus- 
MC-38 (n=5) (1×108 particles/tumor + 1×108 
vp/tumor), ICG (10 ug/mL), EV-ICG-LL/2 (1×108 
particles/tumor + 10 ug/mL). Treatment groups were 
administered i.v (50 µl) to mice with tumors (one 
tumor per mouse about 5 mm in diameter). Brain, 
tumors, livers and serum from C57BL/6 mouse were 





collected for quantitative real time PCR (LighCycler 
480, Roche, Basel, Switzerland). 
Patient samples  
Human liver tissues were obtained during 
planned surgical interventation for benign liver 
diseases (mainly cholecystectomy for stones or 
chronic cholecistis) performed by the 
Hepato-Pancreato-Biliary Unit at the Istituto 
Nazionale Tumori, Milan. The use of human materials 
was conducted in accordance with the declaration of 
Helsinki. 
In vivo and ex vivo imaging 
The in vivo fluorescence imaging was carried out 
24 h post i.v. EV treatments, mice were anaesthetized 
using Isofluorane (Isofluorane-Vet; Merial, Lyon, 
France) and kept under anesthesia during imaging 
sessions carried out with the Imaging System (5 min 
for dorsal view and 5 min for ventral view) (IVIS 
Lumina II Quantitative Fluorescent Imaging; 
PerkinElmer, Waltham, MA, USA) with suitable 
filters (Cy5.5, ICG) and following the manufacturer 
instructions for fluorescence background subtraction. 
For the ex vivo imaging acquisition of fluorescence 
mice were euthanized by cervical dislocation and ex 
vivo imaging of the selected organs was carried out 
immediately after death over an exposition time of 1 
second. The quantification was done with Living 
Image Software 3.2 (PerkinElmer). 
Quantitative real-time PCR 
qPCR for adenovirus E4 copy number was 
carried out according to the protocol previously 
described [44] primer FW: 5’-GGA GTG CGC CGA 
GAC AAC-3’, primer RV: 5’-ACT ACG TCC GGC 
GTT CCA T-3’, probe E4: 5’-(6FAM)-TGG CAT GAC 
ACT ACG ACC AAC ACG ATC T- (TAMRA)-3’[45]. 
Total DNA was extracted from LL/2 cells 48 h post 
treatment in vitro and from resected brains, tumors, 
livers, blood from C57BL/6 mouse model after 24h 
post treatment, using the QIAamp DNA Blood Mini 
Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s protocol. Subsequently isolated DNA 
was analyzed for adenoviral E4 copy number 
normalized to murine beta-actin (liver, blood) 
((primer FW: 5’-CGA GCG GTT CCG ATG C-3’, 
primer RV: 5’-TGG ATG CCA CAG GAT TCC AT-3’, 
probe murine beta-actin: 5’-(6FAM)-AGG CTC TTT 
TCC AGC CTT CCT TCT TGG-(TAMRA)-3’. Samples 
were analyzed using LighCycler qPCR machine 
(LighCycler 480, Roche, Basel, Switzerland). 
Quantitative assay for detection of hCD40L 
Quantitative analysis of human CD40L 
(hCD40L) produced by the investigated oncolytic 
adenovirus was performed using Elisa kit (Abcam, 
ab99991) as previously described [41]. Standards and 
samples were pipetted into the wells to the 
immobilized antibody. The wells were washed and a 
biotinylated anti-hCD40L antibody was added. After 
washing away the unbound biotinylated antibody, 
horse radish peroxidase (HRP)-conjugated 
streptavidin was pipetted to the wells. The wells were 
again washed, a TMB substrate solution was added to 
the wells, and color development was monitored at 
450 nm, which was proportional to the amount of 
bound CD40L. The mean absorbance for each set of 
standards and samples were calculated after 
subtracting the absorbance of the negative control. 
The standard curve was plotted immediately after 
stopping the reaction, with standard concentration on 
the y-axis and absorbance on the x-axis, and the 
best-fit straight line was drawn through the standard 
points. 
Statistical analysis 
Statistical significance was analyzed by using 
one-way ANOVA with Tukey’s Multiple Comparison 
test and nonparametric Mann–Whitney test. All 
statistical analysis, calculations and tests were 
performed using GraphPad Prism 5 (GraphPad 
Software, San Diego, CA).  
Results 
Production of LL/2 and MC-38 derived EV 
formulations and their ability to induce 
immunogenic cell death 
We previously demonstrated that murine lung 
cancer cell-derived EVs could be a useful carriers for 
the systemic delivery of OVs to the neoplastic tissue 
and that EVs are able to induce immunogenic cell 
death in vitro and a marked anti-cancer effect in vivo 
[24] through a mechanism that involves the 
stimulation of a localized tumor-associated 
inflammatory response [24]. In these previous studies, 
tumour-derived EVs were used to deliver OVs in vitro 
and in vivo to the same tumour that originated the 
vesicles; in the current work, we aimed to test the 
possibility of targeting different tumour types. To this 
end, we used a mouse lung cancer (LL/2) and colon 
cancer (MC-38) cells to produce EV formulations and 
to generate tumour models in immunocompetent 
syngeneic mice (C57Bl/6). EV formulations were 
characterized respect to the particle size distribution 
by using NTA (Figure 1A-B), and all formulations 
were within the range of 50 to 400 nm (Figure 1A). 
The free viruses in the EV-Virus formulations were 
inactivated with NaOH-treatment, a procedure that 
we previously shown to preserve the EV integrity and 





the activity of the encased virus [24]. Further EV 
characterization was carried out by western blot 
analysis demonstrating the presence of specific EV 
biomarkers such as TGS101, CD63 and CD9 in the 
preparation (Figure 1C). Moreover, dynamic light 
scattering analysis revealed that EVs and EV-Virus 
had a negative zeta-potential of approximately -40 
mV, while the free virus had a zeta-potential of -20 
mV (Figure 1D), which is in concordance with our 
previous results [24]. Finally, cryo-EM experiments 
directly demonstrated the EV integrity and the 
incorporation of the virus within the vesicles 
(Figure 1E). 
These experiments confirmed that the 
encapsulation of OVs had only minimal effects on size 
and charge of the murine EVs, similar to what was 
observed with formulations previously obtained with 
human and murine lung cancer EVs [24,42]. To 
evaluate the anti-tumour activity of the LL/2 and 
MC-38 derived EV formulations, we tested their 
cytotoxic effects with the MTS cell viability assay with 
the EVs of the same origin and by crossing the 
treatments. In particular, the EV-formulations 
obtained from LL/2 cells (EVs-LL/2, EV-Virus-LL/2) 
were used to treat MC-38 cells, while the 
EV-formulations obtained from MC-38 cells 
(EVs-MC-38, EV-Virus-MC-38) were used to treat 
LL/2 cells. Surprisingly, the EV-Virus formulation 
showed the highest anti-cancer activity irrespective of 
the cell lines that were generating the EVs, as 
compared to cells treated with the Virus alone (Figure 
2 A-B) (p<0,001), suggesting that the cell cytotoxicity 
of the EV formulations was not cell line dependent. 
The success of the cancer treatment relies on the 
induction of immunogenic tumor cell death (ICD) and 
induction of anti-tumor immune responses. Therefore 
to evaluate whether the EV-formulations could 
induce an immunogenic cell-death program, the 
expression of specific markers, such as exposure of 
calreticulin on the cell surface and extracellular 
release of ATP [46], was measured on murine lung 
and colon cancer cells respectively treated with 10 
particles/cell EV-LL/2 and EV-MC-38, Virus, 
EV-Virus-LL/2, EV-Virus-MC-38. Again, the highest 
immunogenic cell death on tumour cells was 
observed with EV-Virus-LL/2 and EV-Virus-MC-38 
treatments irrespectively from the cell line treated 
(Figure 2C-D-E-F), while the EVs administered alone 
did not influence immunogenic cell death. In this 
study, we demonstrated that Virus containing 
formulations were able to induce ICD to the greatest 
extent in comparison to EV alone. A trend to increase 
of the immunogenic cell death marker expression (Fig 
2C-D-E-F), although statistically non-significant, was 
constantly observed also for the EV-Virus treatments 
when compared to the treatments with virus alone. 
This slight increase could be ascribed to the ability of 
EVs to concentrate the virus at the tumor site due to 
the EV-dependent tumor tropism[23]. These data 
indicated that all EV formulations, independent of 
their origin, were able to induce an immunogenic cell 
death program, thereby suggesting that the tumor 
uptake of the vesicles depended on a general 
mechanism shared by all cancer types.  
 
 
Figure 1. Size and net-charge of murine lung and colon cancer derived extracellular vesicles. (A-B) Size distribution of EVs, EV-Virus, and Virus samples was 
determined by using a Nano Tracking Analysis (NTA) instrument. (C) Immunoblot analysis of exosome markers TSG101, CD63 and CD9 in the different EV-preparations. (D) 
The surface charge of the EVs-LL/2, EVs-MC-38, Virus, EV-Virus-LL/2 and EV-Virus-MC-38 was measured using a ZetaSizer Nano Malvern instrument. Bars represent the means 
+/- SD of three experiments. (E) Cryo-EM image of EVs and EV-Virus (scale bar 100 nm) acquired with a FEI Talos Arctica 200 kV FEG electron microscope equipped with a FEI 
Falcon 3EC direct electron detector and Volta Phase-plate  






Figure 2. In vitro anti-tumour properties of EVs as drug delivery vehicles. (A) Antineoplastic efficacy was measured by MTS cell viability assay in the LL/2 and MC-38 cell 
lines. Cell viability has been expressed as the percentage of the viable cells, normalized on the average measurement of the control group (set as the reference 100%). 
Measurements have been performed 72 h post-treatment. (C-D) Extracellular ATP was measured from the indicated cell line supernatants, 48h post-treatment using ATP 
determination kit. (E-F) Calreticulin exposure on outer cell surface of the murine cancer cells was measured 24h post-treatment by flow cytometer. Bars represent the means 
+/- SD of three experiments; *p< 0.05, ***p< 0.001. 
 
Homologous tumour-tropism of murine 
cancer-derived EVs  
Previous data showed a marked homologous 
tumour tropism of EV formulations, when given i.v. 
to mice bearing a lung tumour derived from the same 
cell line [24,42]. To demonstrate that also our 
preparation of colon cancer EVs had the same tumor 
tropism reported in our previous works on lung 
cancer, we have encapsulated the fluorescent dye 
DiIC18(5); 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo-
dicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) 
to the EVs and obtained the EV-DiD-LL/2 and 
EV-DiD-Virus-MC-38 formulations [24,47]; then, we 
evaluated the fluorescence biodistribution after i.v. 
administration of 1x108 particles/tumour to the 
C57Bl/6 wild type mice engrafted with the 
corresponding cell line originating the EVs. The in 
vivo imaging acquisitions of fluorescence were carried 
out 24h post-treatment (Figure 3A-D and Figure S1A) 
and acquisitions showed a specific signal arising from 
the tumour, suggesting that the probe was selectively 
accumulated in the neoplastic tissue when animals 
were treated with both EVs and EV-Virus particles. 
This effect was then confirmed by ex vivo imaging 
analysis of the fluorescence emitted by the dissected 
organs that showed a positive signal originating 
mostly from the tumour and the liver (Figure 3 
B-C-E-F and Figure S1B); when administered i.v. the 
dye alone (not formulated into EVs) did not produce a 
preferential accumulation of the fluorescence in any 
tissue including the tumor, with the exception of liver, 
where the fluorescent signal could be attributed to 
autofluorescence since a similar fluorescent emission 
could also be detected in animals that were not 
injected with the probe (Figure S2) [24,42].  
Heterologous tumour-tropism of murine 
cancer-derived EVs 
The ability of EVs to specifically target the 
tumour site prompted us to verify whether their 
biodistribution was dependent from the tumor 
originating the vesicles. To this end, C57BL/6 mice 
bearing lung cancer (originating from LL/2 cell line) 
were i.v treated with colon cancer (MC-38)-derived 
EV-formulations (EV-DiD-Virus-MC-38) (Figure 
4A-C); conversely, another set of mice bearing colon 
cancer (originating from MC-38 cell line) were i.v 
treated with lung cancer (LL-2) derived 
EV-formulations (EV-DiD-Virus-LL/2) (Figure 4D-F). 





The in vivo imaging acquisitions of fluorescence were 
carried out 24h post-treatment (Figure 4A-D). 
Interestingly, imaging showed a fluorescent 
accumulation in the tumour (Figure 4A-D), in 
addition to the autofluorescence of the liver (Figure 4 
B-C-E-F). Taken together these results were indicative 
of a heterologous tropism of the EVs selectively 
recognizing the neoplastic tissue.  
 
 
Figure 3. Murine colon cancer derived EVs formulations (+/- OVs) show a positive fluorescent signal at the tumour site. (A) Representative images of the 
photon emission (fluorescence) in the tumor area of C57BL/6 previously s.c. injected with 1. 106 MC-38 cells and i.v treated with EV-DiD-MC-38. (B) Representative images of 
the photon emission in 7 organs explanted from mice treated with EV-DiD-Virus-MC-38. (C) Quantification of fluorescence emission from explanted organs assessed using the 
Living Image Software (PerkinElmer) and CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). The results 
represent mean +/- SD. (D) Representative images of the photon emission (fluorescence) in the tumour area of C57BL/6 previously s.c. injected with 1. 106 MC-38 cells and i.v 
treated with EV-DiD-Virus-MC-38. (E) Representative images of the photon emission in 7 organs explanted from mice treated with EV-DiD-Virus-MC-38. (F) Quantification of 
fluorescence emission from explanted organs assessed as described in (C).  
 
Figure 4. Colon and lung cancer derived EV-formulations are able to target lung tumour sites. (A) Representative images of the photon emission (fluorescence) in 
the tumour area and in 7 organs explanted from murine lung cancer (LL/2) bearing mice i.v. treated with EV-DiD-Virus-MC-38. (B) Representative images of the fluorescence 
emitted by 7 organs explanted from mice i.v. treated with EV-DiD-Virus-MC-38. (C) Quantification of fluorescence emission from explanted organs assessed using the Living 
Image Software (PerkinElmer) and CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). The results represent 
the mean +/- SD. (D) Representative images of the photon emission (fluorescence) in the tumour area and (E) in 7 organs explanted from murine colon cancer (MC-38) bearing 
mice i.v. treated with EV-DiD-Virus-LL/2. (F) Quantification of fluorescence emission from explanted organs assessed using the Living Image Software (PerkinElmer) and 
CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). The results represent the mean +/- SD. 





In agreement with this conclusion, the 
replication of the virus measured by qPCR showed 
the highest concentration of adenoviral DNA copies 
in the tumour of mice treated with EV-Virus 
formulations, suggesting that the virus was 
replicating locally (approx. 40,000 DNA copies 
detected, p<0.001); while no virus was detectable in 
liver and serum of the same animals (Figure S3A-B). 
Furthermore, since the adenoviral vector has been 
armed with human CD40 ligand (CD40L), we have 
performed quantification measurements of this 
exogenous protein specifically produced by the virus: 
the analysis provided consistent results compared 
with the qPCR data: the highest concentration of the 
CD40L was found in tumour tissues (Figure S3C-D) 
5-fold higher compared to the one found in serum and 
liver. The basal expression of CD40L in liver and 
serum is likely due to a cross-talk of the antibody used 
for the ELISA with the endogenous mouse CD40L 
protein; nevertheless, the enrichment of CD40L 
protein in the tumor was indicative of the additional 
expression of this protein due to the virus itself. 
Taken together these results confirmed the 
targeted delivery and tumor specific replication of the 
virus encased within EVs. 
Murine cancer derived EV-formulations also 
recognize tumours spontaneously arising from 
the tissue of a genetically modified mouse 
(MMTV-NeuT)  
In previous experiments, we have tested the 
cancer-specific heterologous tropism of EVs in 
tumours originated by syngeneic engraftment. These 
tumours may differ from those spontaneously 
originating in the tissue in terms of encapsulation or 
neo-vascularization [48]: these differences could have 
affected the permeability of the fluorescent dye to the 
tumour. Thus, we tested the ability of EVs to target 
the tumor site in a transgenic mouse 
model (MMTV-NeuT mice), which displayed 
palpable invasive carcinoma in their mammary 
glands (Figure 5 A-B). Our results showed that the 
EV-DiD-LL/2 formulation was able to accumulate 
mainly in the mammary tumour, when compared to 
the free DiD, which showed only the liver 
autofluorescence [24,42] (Figure 5 A-B-C). Due to the 
autofluorescence problems of DiD detection in liver, 
to minimize the background we decided to use the 
near infrared fluorescent (NIR) indocyanine green 
(ICG) for the characterization of the whole-body 
biodistribution of EV formulations. The results 
displayed a tumour-specific tropism when the 
fluorescent probe was loaded into the vesicles that we 
could not detect when ICG was administered alone 
(Figure 5D-E-F). Thus, we concluded that ICG could 
be used for the evaluation of EV biodistribution and 
was giving a significantly less background when 
compared to DiD.  
Interestingly, the biodistribution profile of EVs 
did not depend on the tumour engraftment but 
showed a heterologous tumour-tropism also in 
spontaneously occurring tumours in the mammary 
tissue. Finally, we tested whether EVs derived from a 
human cancer cell line had cross-species homing 
capability: to this end, we loaded the ICG dye in 
human lung cancer derived EVs (EV-ICG-A549) and 
measured their biodistribution 24 h after treatment in 
MMTV-NeuT mice bearing spontaneous mammary 
cancer. The results demonstrated that the human EVs 
were also able to target the mouse mammary tumor 
(Figure 6A-B-C). The generalized tumor tropism of 
EVs could be attributed to a peculiar phagocytic or 
other activities present in the transformed cells 
[9,14,49]; to rule out this hypothesis we have loaded 
ICG into EVs isolated from a human biopsy of a 
healthy liver tissue. When injected into C57BL/6 mice 
these non-cancerous derived EVs were unable to 
accumulate at the cancer site (Figure S4-S5). 
Moreover, also EVs isolated from non-transformed 
human myoblasts C2C12 did not show any 
accumulation at the neoplastic tissue (Figure S6), 
again suggesting that the tumour recognition was not 
a feature depending only on a peculiar cancer activity 
(e.g. augmented phagocytosis of cancer cells), but 
required the specific generation of the EVs in cancer 
cells as well as specific features present in neoplastic 
tissues.  
Discussion  
The heterologous and cross-species homing of 
tumour-derived EVs might reflect their role in the 
intercellular communication contributing to the 
transformation mechanism of the normal tissue [50]. 
Indeed, it has been demonstrated that 
tumour-derived EVs can promote the intercellular 
cross-talk of cancer-related molecules contributing to 
the acquisition of the different hallmarks of cancer 
[7,8]. However, the role of the EV interactions among 
the heterogeneous cell types characterizing the 
tumour tissues has not been thoroughly elucidated to 
date [51]. It has been reported that EVs originated 
from some immune-cells such as NK or T-cells 30 and 
from mesenchymal stem cells can bear receptors able 
to reiterate the tumour tropism of their parental 
cells 29,46. In this case, it is suggested that EVs from 
different cell sources may potentially have different 
innate homing capabilities in vivo by adopting the 
homing pattern of the parental cell of origin, through 
the acquisition of the same repertoire of surface 
receptors and extracellular matrix-binding proteins 





present in their parental cell [33]. Thus, the homing 
capability of the vesicles may reflect their functional 
properties that differ considering EVs generated by 
the tumour micro-environment as compared to those 
originating from non-malignant cells. These 
differences have been extensively described and 
include distinct biogenesis mechanisms [16,17], cargo 
uptake [18,19] and the expression of specific 
membrane proteins and antigens [20,21]. It is 
therefore conceivable that these peculiar 
characteristics of cancer-derived EVs may direct their 
tropism; thus, EVs originating from different tumours 
are expected to have different membrane proteins and 
antigens on their surface supporting the hypothesis of 
a strict tissue specific tropism [20,21]. Conversely, our 
data indicate that this hypothesis is not supported and 
suggest a conservation of the homing features 
independent of the tumour type or even the species 
originating the vesicles. This finding might reflect the 
existence of a biological mechanism that allows 
heterogeneous cells composing the tumour to 
communicate with one another through the release of 
EVs [53], overcoming natural barriers that are 
physiologically restricting the communications 
through EVs.  
 
 
Figure 5. Cancer derived EV-formulations loaded with different fluorescent markers are able to target the mammary tumors in MMTV-NeuT mice. (A-B) 
Representative images of the photon emission (fluorescence) in the tumour area and in 7 organs explanted from the MMTV-NeuT mice i.v. treated with EV-DiD-LL/2 versus DiD. 
(C) Quantification of fluorescence emission from explanted organs assessed using the Living Image Software (PerkinElmer) and CCD-camera (IVIS Lumina II Quantitative 
Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). (D-E) Representative images of the photon emission (fluorescence) in the tumour area and in 7 
organs explanted from MMTV-NeuT mice i.v. treated with EV-ICG-Virus-LL/2 versus ICG. (F) Quantification of fluorescence emission from explanted organs assessed using the 
Living Image Software (PerkinElmer) and CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). 
 
Figure 6. Human lung cancer derived EVs are able to target the mammary tumors in MMTV-NeuT mice. (A) Representative image of the photon emission 
(fluorescence) in the tumour area of MMTV-NeuT mice i.v treated with EV-ICG-A549. (B) Representative image of the photon emission (fluorescence) in 7 organs explanted 
from genetic breast cancer mice. (C) Quantification of fluorescence emission from liver and tumour tissue assessed using the Living Image Software (PerkinElmer) and 
CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA). 





A recent work from Hoshino and collaborators 
reported that cancer-derived EVs are able to set the 
niche in distal organs to receive metastatic cells; this 
ability is due to the presence of a specific repertoire of 
integrins on their surface that provide the needed 
tissue-specific homing abilities for reaching the organ 
site of metastasis and delivering the vesicles content 
[15]. In our experiments, we have not observed this 
key mechanism underlying cancer spreading, likely 
because of the large number of EVs used in the 
systemic delivery we adopted; this, together with the 
sensitivity limitation of our method of detection, 
could have limited our ex vivo measures only to the 
large dye accumulation we observed in tumour 
tissues; in this condition, we likely failed to detect 
small signals coming from the niches present in 
normal tissues recognized as metastatic sites and 
described by the study of Hoshino and collaborator.  
In our case the cancer-derived EV homing to 
neoplastic tissue could be either due to a 
ligand/receptor interaction or to other unspecific 
mechanisms: for instance the tumour uptake of the 
vesicles may occur because of the increased 
phagocytic activity of the recipient cells [14]. Our 
experiments using EVs generated from a healthy 
tissue have ruled out the latter possibility: indeed, in 
this case, we would have expected a general uptake 
also of these “normal” vesicles by the neoplastic 
tissues that we have not observed (Figure S4). 
Therefore, the specific homing of our cancer-derived 
EVs may be due to a specific ligand-receptor 
interaction similar to that previously observed for 
other EV homing abilities [15,49]. In this case, we 
might hypothesize the presence of a tumour-specific 
“ligand” exposed on the EV surface during their 
biogenesis in the cancer cell and a tumour-specific 
“receptor” already sitting on the surface of different 
types of cancer cells.  
The identification of the mechanisms underlying 
the specific behaviour of cancer-derived-EVs is 
currently one of the major challenges facing in the 
field of EV biology [54] and the cancer tropism of EVs 
is an important issue to be considered not only for a 
better understanding of the role of EVs in tumour 
cell-to-cell communication, but also for the use of EVs 
as a tool for the tumour-specific delivery of 
theranostic agents [23,24,42]. At the moment the 
tropism and internalization mechanisms of 
tumor-derived EVs can only be speculated: taken 
together, our results suggest the existence of a specific 
“general” tumor antigen expressed across species that 
is recognized by a “general” ligand present on the EVs 
surface. If this will be proven true, the 
characterization of such a ligand-receptor interaction 
will provide clues also for understanding the 
mechanism responsible of the internalization of the 
dye in tumour cells. 
Our work, by highlighting the possible existence 
of a selective ligand-receptor mechanism responsible 
for the tumour-tropism, paves the way for future 
research aimed at constructing biocompatible 
nanovesicles with a cancer-selective homing. We 
demonstrated that EVs may be loaded with 
therapeutics such as OVs and diagnostic agents 
already approved by regulatory agency for their use 
in humans, such as ICG; this proof-of-principle 
experiment can be instrumental for future 
theranostics applications, for example in 
intraoperative imaging [55], where the diagnostic 
delivery of ICG may be combined with the loading of 
drugs (e.g. paclitaxel [56] or doxorubicin [57]) or 
radiotherapeutic isotopes (e.g. 99mTc [58]) for curing 
tumour micrometastasis and residual neoplastic cells 
eventually remaining in the normal tissue after 
surgery.  
Conclusions 
In this study, we demonstrated the existence of a 
heterologous, cross-species mechanism underlying 
the tumour-specific recognition of cancer-derived EVs 
regardless the tissue of origin. Our study paves the 
way for the description of a novel EV role in 
intercellular communication and to exploit the use of 
EVs in theranostics applications. Clearly, the 
molecular characterization of this mechanism in 
future studies will provide a rational basis for the 
construction of synthetic biocompatible nanoparticles 
avoiding the potential harmful effects associated with 
the use of tumour-derived particles. 
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